Teropavimab
Based on 1 Customer Validation
Teropavimab (3BNC117-LS) is a broadly neutralizing antibody targeting the CD4-binding site of the HIV-1 envelope. Teropavimab binds to the CD4-binding site of HIV-1 gp120 to neutralize viruses, including multidrug-resistant HIV-1. Teropavimab can be used in studies related to HIV-1 infection and multidrug-resistant HIV-1 infection.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.70%
- CAS No.: 2417213-72-8
- 분자량:145.889 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
|
HIV-1 |
In Vitro
Teropavimab (3BNC117-LS) neutralizes pseudotyped SHIVAD8-EO in TZM-bl cells with an IC50 of 0.09 μg/mL, exhibiting activity equivalent to native 3BNC117[2].
Teropavimab neutralizes replication-competent SHIVAD8-EO in TZM-bl cells with an IC50 of 0.11 μg/mL, exhibiting activity equivalent to native 3BNC117[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Teropavimab (7.5 mg/kg; s.c.; single dose, administered in combination with 10-1074-LS) confers protection against repeated low-dose mucosal SHIVAD8-E0 challenge in rhesus macaques, with a median time to virus acquisition of 20 weeks[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Macaca mulatta (Indian genetic origin, 2-4 years of age, negative for MHC alleles Mamu-A01, Mamu-B08, and Mamu-B17)[2]
-
Dosage:20 mg/kg
-
Administration:i.v.; single dose
-
Result:Delayed median time to virus acquisition to 17 weeks (range 11-23 weeks).
Reduced serum concentrations to undetectable levels between weeks 16 and 22 in five of six recipients; one recipient had undetectable levels by week 5 due to anti-antibody responses.
Achieved a median serum-neutralizing activity of 1:2,538 at 1 week post-infusion.
Extended median serum half-life to 2.8 weeks, a 2.0-fold increase compared to native 3BNC117.
Confirmed significantly greater resistance to SHIVAD8-E0 acquisition compared to untreated controls (P = 0.004).
-
Animal Model:Macaca mulatta (Indian genetic origin, 2-4 years of age, negative for MHC alleles Mamu-A01, Mamu-B08, and Mamu-B17)[2]
-
Dosage:7.5 mg/kg (administered in combination with 7.5 mg/kg 10-1074-LS)
-
Administration:s.c.; single dose
-
Result:Delayed median time to virus acquisition to 20 weeks (range 15-24 weeks for five of six macaques).
Reduced serum concentrations to undetectable levels between weeks 5 and 9 in five of six recipients; one recipient maintained measurable levels until week 18.
Induced anti-Teropavimab antibodies in four of six macaques 4 to 6 weeks post-administration, leading to rapid clearance of the antibody.
Confirmed significantly greater resistance to SHIVAD8-E0 acquisition compared to untreated controls (P = 0.004).
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Envelope glycoprotein gp120 Protein, HIV-1 (AAC31819, HEK293, His, HY-P76390) can bind Teropavimab. The EC50 for this effect is 196.4 ng/mL.
Chemical Information
-
CAS No. 2417213-72-8
-
Appearance Liquid
-
분자량 145.889 kDa
-
Color Colorless to light yellow
-
SMILES
[Teropavimab]
-
Synonyms
3BNC117-LS; GS-5423
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (263 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Lorenzi JCC, et al. Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates. Journal of virology. 2021 Mar 01;95(5):e01909-20. [Content Brief]
[2]. Gautam R, et al. A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nature medicine. 2018 May;24(5):610-616. [Content Brief]
[3]. Eron JJ, et al. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. Lancet HIV. 2024 Mar;11(3):e146-e155. [Content Brief]
[4]. Ogbuagu O, et al. Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study. Lancet Microbe. 2026 Mar;7(3):101283. [Content Brief]
[5]. Spagnuolo V, et al. Teropavimab and zinlirvimab sensitivity in people living with multidrug-resistant HIV-1: data from the PRESTIGIO Registry. Microbiology spectrum. 2025 Oct 07;13(10):e0277724. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Teropavimab Related Classifications
HY-P99564 Related Classifications
Powered by Bioz